Victoria Socha

DocwireNews

Among patients with chronic kidney disease (CKD), albuminuria is a strong determinant of kidney and cardiovascular risk in those with and without type 2 diabetes. Early albuminuria reduction may be an indicator of decreased risk in those patient populations.Results of the DAPA-CKD (Dapagliflozin in Patients With Chronic Kidney Disease) trial demonstrated an association between dapagliflozin and a reduction in the risk of kidney and cardiovascular events in patients with CKD; results were similar in those with and without type 2 diabetes.Dominique van Mil and colleagues conducted an analysis of data from DAPA-CKD to examine the risk associations between baseline and early changes in albuminuria and kidney outcomes in patients with CKD with and without diabetes. Results were reported during a poster session at the American Society of Nephrology Kidney Week 2023 in a poster titled Associations Between Albuminuria and Clinical Outcomes in Patients With CKD With and Without Diabetes: New Insights From DAPA-CKD.The DAPA-CKD trial included 4304 patients with and without type 2 diabetes with urinary albumin-to-creatinine ratio (UACR) 200 to 5000 mg/g and estimated glomerular filtration rate (eGFR) 25 to 75 mL/min/1.73 m2. Participants were randomized to receive dapagliflozin 10 mg or placebo daily in combination with standard of care, and were followed for a median 2.4 years.Multivariable adjusted Cox regression analyses were used to identify associations between baseline UACR, and early change in UACR (baseline to month 4), and the primary outcome (&ge;50% decline in eGFR, end-stage kidney disease, death from a renal or cardiovascular cause).There was an association between every doubling of baseline UACR and a near doubling of risk: hazard ratio (HR), 1.89; 95% CI, 1.71-2.08 in patients with type 2 diabetes and HR, 1.84; 95% CI, 1.54-2.20 in patients without type 2 diabetes. In participants with diabetes, dapagliflozin reduced UACR (placebo-adjusted) from baseline to month 4 by 35.7% (95%cI, 29.0%-42.5%). In those without diabetes, the reduction was 19.7% (95% CI, 10.6%-38.8%). In both treatment groups, there was a large between-individual variation. The HR for every 50% decline in UACR from baseline to month 4 was 0.86 (95% CI, 0.79-0.93) for participants with diabetes and 0.70 (95% CI, 0.59-0.83) for those without diabetes.In summary, the authors said, &ldquo;In patients with CKD with and without type 2 diabetes, higher baseline albuminuria was associated with a higher risk of progressive kidney disease or cardiovascular death, and early albuminuria reduction was associated with a decreased risk. Because dapagliflozin reduced clinical outcomes in patients with and without type 2 diabetes but reduced albuminuria to a larger degree in those with type 2 diabetes, these findings suggest that the clinical benefits gained via dapagliflozin&rsquo;s albuminuria-reducing effects are more potent among patients with type 2 diabetes.&rdquo;Source: van Mil D, Vart P, Schechter M, er al. Associations between albuminuria and clinical outcomes in patients with CKD with and without diabetes: new insights from DAPA-CKD. TH-PO1057. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2023; November 2, 2023; Philadelphia, Pennsylvania. Funding was provided by AstraZeneca plc.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Early Albuminuria Reduction and Decreased Risk of Progressive Kidney Disease

Part of NephTimes Diseases and Conditions

Diabetes and Hypertension

Results of a data analysis examining the risk associations between baseline changes in albuminuria and kidney outcomes in patients with CKD with and without diabetes.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe